SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Recruiting

Phase 1

Phase 2

AR-501SAD and MAD of Inhaled AR-501 in Health Adults and P. Aeruginosa Infected Cystic Fibrosis Subjects

Sponsor:

Aridis Pharmaceuticals, Inc.

Code:

NCT03669614

Conditions

Cystic Fibrosis

Eligibility Criteria

Sex: All

Age: 18 - 49

Healthy Volunteers: Accepted

Interventions

Inhaled AR-501

Inhaled Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-29. This information was provided to ClinicalTrials.gov by Aridis Pharmaceuticals, Inc. on 2023-03-09.